Registry for patients with treatment-resistant depression and OCD receiving interventional therapies
University of Iowa Interventional Psychiatry Service Patient Registry
This study is testing different treatments like ECT, TMS, and ketamine to see how they help people with treatment-resistant depression and OCD feel better.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 18 Years to 99 Years |
| Sex | All |
| Sponsor | University of Iowa Academic / other |
| Locations | 1 site (Iowa City, Iowa) |
| Trial ID | NCT04480918 on ClinicalTrials.gov |
What this trial studies
This study examines the effects of various interventional therapies, such as electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), and ketamine treatments, on patients with treatment-resistant depression (TRD) and obsessive-compulsive disorder (OCD). It aims to collect and analyze biomarkers, including neurobehavioral tests and neuroimaging, to better understand treatment responses. By identifying multimodal biomarkers, the study seeks to enhance personalized treatment approaches for individuals suffering from major depression and related disorders.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18-99 with a clinical diagnosis of major depressive disorder, bipolar disorder, or treatment-resistant OCD.
Not a fit: Patients with primary neuropsychiatric diagnoses other than major depressive disorder or bipolar disorder, or those with serious unstable medical conditions, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more effective, personalized treatment options for patients with treatment-resistant depression and OCD.
How similar studies have performed: Previous studies have shown promising early results in identifying biomarkers for treatment response in similar patient populations, but this approach aims to enhance predictive power through multimodal analysis.
Eligibility criteria
Show full inclusion / exclusion criteria
INCLUSION CRITERIA: 1. 18-99 years of age 2. English-speaker with a level of understanding sufficient to agree to clinical treatment with a treatment modality offered by the Interventional Psychiatry Service, all required research procedures, and sign an informed consent document 3. Clinical diagnosis of a major depressive episode in the context of major depressive disorder or bipolar disorder or treatment-resistant OCD evaluated by a provider on the Interventional Psychiatry Service and felt to be an appropriate candidate for clinical treatment with a treatment modality offered by the Interventional Psychiatry Service. EXCLUSION CRITERIA: 1. Age less than 18 years 2. A primary neuropsychiatric diagnosis that is not either major depressive disorder or bipolar disorder 3. Serious, unstable medical conditions/problems including hepatic, renal, gastroenterologic, respiratory, cardiovascular, endocrinologic, neurologic, immunologic, or hematologic disease, e.g. uncontrolled asthma, uncontrolled hyper/hypothyroidism or active cancer. 4. Involuntary commitment to psychiatry inpatient units 5. If patients have one or more of the following MRI Exclusion criteria, they will not be able to participate in those aspects of this study: 1. The presence of an implanted device including pacemaker, coronary stent, defibrillator, or neurostimulation device that is not MRI-compatible 2. The presence of ferromagnetic objects in the body, i.e. bullets, shrapnel, and/or metal slivers 3. Clinically-significant claustrophobia 4. Clinically-significant hearing loss 5. Pregnant or nursing women or women of child bearing potential not using at least one medically accepted means of contraception (to include oral, injectable, or implant birth control, condom or diaphragm with spermicide, intrauterine devices (IUD), tubal ligation, abstinence, or partner with vasectomy) 6. The presence of any medical illness likely to alter brain morphology and/or physiology (e.g., hypertension, diabetes) even if controlled by medications
Where this trial is running
Iowa City, Iowa
- University of Iowa Health Care — Iowa City, Iowa, United States (Recruiting)
Study contacts
- Principal investigator: Mark J Niciu, M.D., Ph. D. — University of Iowa Hospitals & Clinics
- Study coordinator: Karin Nielsen, MS
- Email: karin-nielsen@uiowa.edu
- Phone: 319-384-6521
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.